PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Fucoidan administration in obese mice reduced body weight gain, fat accumulation, and hepatic steatosis while improving glucose tolerance and insulin sensitivity [PMID:35907465, PMID:40758868]
Alginate from S. fusiforme demonstrated inhibitory effects against human adenovirus type 7 in vitro [PMID:35321314]
S. fusiforme polysaccharides, in combination with cordycepin and lactoferrin, improved lung pathology and decreased viral load in a murine model [PMID:40589746]
Exosome-like nanoparticles (SELNs) alleviated symptoms of Citrobacter rodentium-induced colitis by suppressing the TLR4/MyD88/NF-κB pathway [PMID:41526538]
Drinking and skin application of extracts significantly increased hair growth rate and follicle length in C57BL/6 mice [PMID:36800993]
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 36869543 (2023) — A review of volatile compounds in edible macroalgae. · Food research international (Ottawa, Ont.)
- 2.PMID: 37876153 (2023) — Bioactivities of the Popular Edible Brown Seaweed Sargassum fusiforme: A Review. · Journal of agricultural and food chemistry
- 3.PMID: 34359532 (2021) — Hizikia fusiformis: Pharmacological and Nutritional Properties. · Foods (Basel, Switzerland)
- 4.PMID: 33133523 (2020) — Therapeutic and nutraceutical potentials of a brown seaweed Sargassum fusiforme. · Food science & nutrition
- 5.PMID: 40758868 (2025) — Sargassum fusiforme Fucoidan Ameliorates Obesity-Associated Metabolic Dysfunction via a Tauroursodeoxycholic Acid-Mediated TGR5-cAMP-PKA Signaling Pathway.